Anti-NALF1/ FAM155A monoclonal antibody

Anti-NALF1/ FAM155A antibody for FACS & in-vivo assay

Target products collectionGo to FAM155A/FAM155A products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP0429-Ab-1/ GM-Tg-hg-MP0429-Ab-2Anti-Human FAM155A monoclonal antibodyHuman
GM-Tg-rg-MP0429-Ab-1/ GM-Tg-rg-MP0429-Ab-2Anti-Rat FAM155A monoclonal antibodyRat
GM-Tg-mg-MP0429-Ab-1/ GM-Tg-mg-MP0429-Ab-2Anti-Mouse FAM155A monoclonal antibodyMouse
GM-Tg-cynog-MP0429-Ab-1/ GM-Tg-cynog-MP0429-Ab-2Anti-Cynomolgus/ Rhesus macaque FAM155A monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP0429-Ab-1/ GM-Tg-felg-MP0429-Ab-2Anti-Feline FAM155A monoclonal antibodyFeline
GM-Tg-cang-MP0429-Ab-1/ GM-Tg-cang-MP0429-Ab-2Anti-Canine FAM155A monoclonal antibodyCanine
GM-Tg-bovg-MP0429-Ab-1/ GM-Tg-bovg-MP0429-Ab-2Anti-Bovine FAM155A monoclonal antibodyBovine
GM-Tg-equg-MP0429-Ab-1/ GM-Tg-equg-MP0429-Ab-2Anti-Equine FAM155A monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP0429-Ab-1/ GM-Tg-hg-MP0429-Ab-2; GM-Tg-rg-MP0429-Ab-1/ GM-Tg-rg-MP0429-Ab-2;
GM-Tg-mg-MP0429-Ab-1/ GM-Tg-mg-MP0429-Ab-2; GM-Tg-cynog-MP0429-Ab-1/ GM-Tg-cynog-MP0429-Ab-2;
GM-Tg-felg-MP0429-Ab-1/ GM-Tg-felg-MP0429-Ab-2; GM-Tg-cang-MP0429-Ab-1/ GM-Tg-cang-MP0429-Ab-2;
GM-Tg-bovg-MP0429-Ab-1/ GM-Tg-bovg-MP0429-Ab-2; GM-Tg-equg-MP0429-Ab-1/ GM-Tg-equg-MP0429-Ab-2
Products NameAnti-FAM155A monoclonal antibody
Formatmab
Target NameFAM155A
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-FAM155A benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species NALF1/ FAM155A VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP0429
    Target NameFAM155A
    Gene ID728215,270028,498667,100423122,100688758,101088903,616912,100051408
    Gene Symbol and Synonyms6430500D16,FAM155A,NALF1,NLF-1,NLF1,RGD1559498,Tmem28
    Uniprot AccessionB1AL88,A4IFM1
    Uniprot Entry NameNALF1_HUMAN,NALF1_BOVIN
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000204442
    Target ClassificationN/A

    The target: FAM155A, gene name: FAM155A, also named as . Predicted to contribute to stretch-activated, cation-selective, calcium channel activity. Predicted to be involved in calcium ion import across plasma membrane. Predicted to be integral component of membrane. Predicted to be active in plasma membrane. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.